Search

Your search keyword '"Chung, Woong Youn"' showing total 394 results
Start Over Author "Chung, Woong Youn" Publication Type Academic Journals
394 results on '"Chung, Woong Youn"'

29. Single‐Port Transaxillary Robotic Modified Radical Neck Dissection (STAR‐RND): Initial Experiences.

Author

Ho, Joon, Kim, Donggyu, Lee, Ji‐Eun, Kim, Jin Kyong, Lee, Cho Rok, Kang, Sang‐Wook, Jeong, Jong Ju, Nam, Kee‐Hyun, and Chung, Woong Youn

Abstract

Objectives: This study aimed to demonstrate the usefulness of single‐port transaxillary robotic modified radical neck dissection (STAR‐RND) for metastatic thyroid cancer, and its potential to make small and invisible surgical wounds possible compared to open modified radical neck dissection. Methods: Between January 2020 and July 2021, 30 thyroid cancer patients who underwent lateral neck dissection surgery with the da Vinci SP at Yonsei University Health System (Seoul, Korea) were studied. Results: All 30 patients, diagnosed with papillary thyroid cancer were women. The average operating time was 293.80 ± 36.58 (min), and the average postoperative hospital stay was 4.77 ± 0.57 (days). All patients were discharged after the expected number of hospitalization days without major complications. Conclusion: STAR‐RND is technically feasible and safe with a short length of the incision. To our knowledge, this is the first report on the use of a single‐port robotic system for modified radical neck dissection. Level of Evidence by Using 2011 OCEBM: 4 Laryngoscope, 133:709–714, 2023 [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Postoperative biochemical remission of serum calcitonin is the best predictive factor for recurrence-free survival of medullary thyroid cancer: a large-scale retrospective analysis over 30 years

Author

Jung, Kyong Yeun, Kim, Seok-Mo, Yoo, Won Sang, Kim, Bup-Woo, Lee, Yong Sang, Kim, Kyung Won, Lee, Kyu Eun, Jeong, Jong Ju, Nam, Kee-Hyun, Lee, Se Hoon, Hah, Jeong Hun, Chung, Woong Youn, Yi, Ka Hee, Park, Do Joon, Youn, Yeo-Kyu, Sung, Myung-Whun, Cho, Bo Youn, Park, Cheong Soo, Park, Young Joo, and Chang, Hang-Seok

Published
2016
Full Text
View/download PDF

38. TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea.

Author

Kim, Min Jhi, Kim, Jin Kyong, Kim, Gi Jeong, Kang, Sang-Wook, Lee, Jandee, Jeong, Jong Ju, Chung, Woong Youn, Kim, Daham, and Nam, Kee-Hyun

Subjects
GENETIC mutation, TELOMERASE, THYROID gland tumors, PAPILLARY carcinoma, AGE distribution, CANCER patients, TREATMENT effectiveness, TRANSFERASES, DISEASE prevalence, DESCRIPTIVE statistics
Abstract

Simple Summary: TERT promoter mutation has recently emerged as a promising prognostic biomarker for aggressive papillary thyroid cancer (PTC), along with BRAF B600E mutation. The prevalence of the TERT promoter mutations has been reported as relatively uncommon in Asian countries. We report on a prospective study of the TERT promoter and BRAF V600E mutation in the largest number of subjects with PTC in Korea. We assume that our specific clinical settings and the favorable healthcare environment in Korea led to several distinct findings: the lowest prevalence of TERT promoter mutation ever reported, multifocal gene mutations in bilateral PTCs, and more early-stage papillary microcarcinomas included in this study. This study indicates that relevant evaluation and treatment strategies should be investigated continuously based on different circumstances. Telomerase reverse transcriptase (TERT) promoter mutation has been investigated for its clinical and prognostic significance in aggressive papillary thyroid cancer (PTC). In this study, we aimed to assess the prevalence, clinicopathologic features, and treatment outcomes of TERT mutation-positive PTCs along with the common BRAF V600E mutation. We performed mutational analyses for BRAF and the TERT promoter in thyroid cancer patients who had undergone surgery at our institution since 2019. We reviewed and analyzed 7797 patients with PTC in this study. The prevalence of BRAF V600E and TERT promoter mutations was 84.0% and 1.1%, respectively. Multifocal gene mutations in bilateral PTCs were identified. TERT promoter mutations were associated with older age, larger tumor size, tumor multifocality, tumor variants, advanced stages, more adjuvant radioactive iodine treatment (RAI), higher stimulated serum thyroglobulin level before RAI, and more uptakes in the regions outside the surgical field on a post-RAI whole-body scan. The coexistence of BRAF V600E and TERT promoter mutations exacerbated all clinicopathologic characteristics. The frequency of TERT promoter mutations was the lowest in this study, compared to previous studies. TERT promoter mutations consistently correlated with aggressive PTCs, and the synergistic effect of both mutations was evident. Specific clinical settings in our institution and in Korea may have led to these distinctive results. Prospective multicenter studies with longer follow-up periods are required to establish valuable oncologic outcomes. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results